"Weight loss drugs can reduce by half the risk of heart patients being hospitalised or dying early, according to the largest study of its kind. The class of drugs, known as GLP-1 agonists, have been found to offer dramatic benefits to heart patients, significantly cutting their risk of falling seriously ill or dying prematurely from any cause. The discovery, revealed at the world's largest heart conference in Madrid, mean they could be given to millions of heart patients to help"
"In the study, US researchers from Mass General Brigham, a nonprofit network of doctors and hospitals headquartered in Boston, analysed real-world data from more than 90,000 heart failure patients who were obese and had type 2 diabetes. The results showed those taking semaglutide were 42% less likely to end up in hospital or die prematurely, compared with a proxy for placebo. In the same study, tirzepatide cut the risk of hospitalisation for heart failure or death from any cause by 58%."
"Weight loss drugs mimic the glucagon-like peptide (GLP) 1 hormone, which makes people feel full, and were initially developed to treat diabetes. In recent years evidence has emerged suggesting they could prove to be lifesaving across a range of conditions beyond obesity. Now the results of major new research, presented at the European Society of Cardiology annual conference, show weight loss drugs could reduce the risk of people with heart conditions being hospitalised or dying early by as much as 58%."
GLP-1 agonist weight-loss drugs substantially lower the risk of hospitalisation and premature death among obese heart failure patients with type 2 diabetes. Researchers analysed real-world data from over 90,000 patients with HFpEF and found semaglutide use associated with a 42% lower combined risk of hospitalisation or death compared with a proxy placebo, while tirzepatide was associated with a 58% reduction. GLP-1 drugs mimic the glucagon-like peptide-1 hormone, promote satiety, and were developed for diabetes. More than 60 million people worldwide have heart failure. The results were presented at the European Society of Cardiology conference and published in JAMA.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]